Key result
ARNI is linked to lower atrial arrhythmia rates vs ARB after first AF ablation.
Why the study?
Upstream treatment for AF is growing, and ARNI is a potential option, motivating an investigation into its effect on atrial electrical instability and structural remodeling in AF.
Does ARNI reduce atrial arrhythmia recurrence compared to ARB in patients undergoing their first atrial fibrillation ablation?
Population
Patients undergoing first AF ablation (n=36 ARNI, n=35 ARB) and 15 beagles with paced AF
Comparison
ARNI vs ARB (and vs control in canines)
Design
Retrospective real-world clinical study and randomized animal experiment
Follow-up
24-week (clinical) and 8-week (animal)
Authors
Loading...
Should not yet change ARB use post-ablation; leaves open ARNI benefit pending RCTs.
Observational (n=71)
Does ARNI reduce atrial arrhythmia recurrence compared to ARB in patients undergoing their first atrial fibrillation ablation?
p-value: p=<0.01
ARNI significantly reduced atrial electrical instability and atrial arrhythmia recurrence compared to ARB in patients following their first radiofrequency catheter ablation for atrial fibrillation.
Zhu et al. (2022) conducted an observational in Atrial fibrillation (n=71). Angiotensin receptor-neprilysin inhibitor (ARNI) vs. Angiotensin II receptor antagonist (ARB) was evaluated on Atrial arrhythmia rate at 24-week follow-up (p=<0.01). ARNI treatment was associated with a significantly lower atrial arrhythmia rate at 24 weeks compared to ARB in patients undergoing their first atrial fibrillation ablation (P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: